ECM
PACB icon

ExodusPoint Capital Management’s Pacific Biosciences PACB Stock Holding History

ExodusPoint Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$1.3M – 2475
2020
Q4 		$1.3M Sell
50,000
-207,000
-81% -$3.52M 0.01% 724
2020
Q3 		$2.54M Buy
+257,000
New +$1.48M 0.05% 332

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

ExodusPoint Capital Management's PACB Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 25,573 shares — an estimated $32K sold.

ExodusPoint Capital Management first reported a position in PACB in Q3 2019 and held it in 6 quarters. The position peaked at $2.76M in Q4 2020. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • ExodusPoint Capital Management reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 25,573 Pacific Biosciences shares in Q3 2025, an estimated $32K.
  • ExodusPoint Capital Management first reported a position in Pacific Biosciences in Q3 2019 and held it in 6 quarters.
  • ExodusPoint Capital Management's Pacific Biosciences position peaked at $2.76M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.